Pediatric Early Phase Clinical Trials Network transfer opportunity for kids with cancer
Official title: Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application
Funded at Cog Research Foundation, LLC · NIH-11418541 · Data updated 2026-11-12
A national network aims to test new cancer therapies in children and adolescents, using genomics, biology, imaging, and patient-reported outcomes to understand how these treatments work in young patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cog Research Foundation, LLC NIH-funded |
| Lab location | 1 site (Arcadia, United States) |
| Project start | August 1, 2025 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $7,254,479 |
| NIH project number | 5UM1CA228823-08 |
| Project ID | NIH-11418541 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children and adolescents with cancer who are eligible for early-phase trials of novel agents, including those with specific antigen targets or antibody-drug conjugates.
✕Less likely to help
Some patients may not benefit if they are not eligible for available early-phase trials or if their cancer does not have a suitable investigational agent.
What this research studies
The Pediatric Early Phase Clinical Trials Network (PEP-CTN) works to identify and develop promising cancer treatments for children and adolescents. Trials will integrate correlative studies in genomics, biology, pharmacology, and imaging, along with patient-reported outcomes, to better understand drug behavior in young patients. Approximately 130 children and teens with cancer will be enrolled each year across sites in the US, Canada, and Australia, with high-quality data and rapid reporting to guide future care. The network builds on existing infrastructure from the Children's Oncology Group to speed translation from early testing to safer, more effective therapies for pediatric cancers. This transfer application supports the administrative and operational framework needed to run these complex early-phase trials at participating institutions.
Why it matters
Potential benefit: Children and adolescents with cancer could gain access to new, potentially beneficial therapies in a learning healthcare environment.
How similar studies have gone: Early-phase pediatric trials have shown feasibility and rapid data transfer through multi-site networks, with translational correlative studies informing dosing and safety.
Where this research is happening
-
Cog Research Foundation, LLC
Arcadia, United States Active
Researchers
- Principal investigator: Fox, Elizabeth — Cog Research Foundation, LLC
- Study coordinator: Fox, Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.